Arcadia Biosciences Company Insiders

RKDA Stock  USD 2.79  0.03  1.09%   
Arcadia Biosciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Arcadia Biosciences stock suggests that vertually all insiders are extremely bullish at this time. Arcadia Biosciences employs about 21 people. The company is managed by 10 executives with a total tenure of roughly 49 years, averaging almost 4.0 years of service per executive, having 2.1 employees per reported executive.

Arcadia Biosciences' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2024-08-01Mark KawakamiAcquired 700 @ 2.06View
2024-02-01Thomas J SchaeferAcquired 700 @ 2.06View
Monitoring Arcadia Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

Arcadia Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arcadia Biosciences' future performance. Based on our forecasts, it is anticipated that Arcadia will maintain a workforce of about 50 employees by January 2025.
 
Yuan Drop
 
Covid

Arcadia Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.3872) % which means that it has lost $0.3872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5265) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.75. In addition to that, Return On Capital Employed is expected to decline to -0.91. At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 5.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.5 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 1.3 M, whereas Net Loss is forecasted to decline to (17.7 M).

Arcadia Biosciences Workforce Comparison

Arcadia Biosciences is rated below average in number of employees category among its peers. The total workforce of Consumer Staples industry is at this time estimated at about 8,251. Arcadia Biosciences adds roughly 21.0 in number of employees claiming only tiny portion of stocks in Consumer Staples industry.
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.15.

Arcadia Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcadia Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcadia Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arcadia Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
1.6667
10
6
 121,400 
 1,487 
2023-03-01
1.0
2
2
 50,700 
 23,000 
2020-06-01
2.0
6
3
 75,868 
 42,000 
2019-09-01
2.3333
21
9
 41,200 
 18,782 
2018-06-01
7.0
7
1
 34,910 
 0.00 
2018-03-01
0.625
5
8
 38,005 
 56,010 
2017-06-01
1.8
9
5
 1,044,920 
 757,604 
2016-09-01
7.0
14
2
 853,585 
 200.00 
2016-06-01
1.1667
7
6
 752,853 
 15,706 
2016-03-01
0.375
3
8
 4,939 
 13,078 
2015-12-01
0.5926
16
27
 244,316 
 309,759 
2015-09-01
0.5349
23
43
 211,149 
 275,727 
2015-06-01
0.2857
22
77
 81,101,033 
 218,011,246 

Arcadia Biosciences Notable Stakeholders

An Arcadia Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arcadia Biosciences often face trade-offs trying to please all of them. Arcadia Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arcadia Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Arcadia Biosciences Management Performance

The success or failure of an entity such as Arcadia Biosciences often depends on how effective the management is. Arcadia Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arcadia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arcadia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.71)(0.75)
Return On Capital Employed(0.86)(0.91)
Return On Assets(0.71)(0.74)
Return On Equity(1.09)(1.03)
Please note, the presentation of Arcadia Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcadia Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Arcadia Biosciences' management manipulating its earnings.

Arcadia Biosciences Workforce Analysis

Traditionally, organizations such as Arcadia Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arcadia Biosciences within its industry.

Arcadia Biosciences Manpower Efficiency

Return on Arcadia Biosciences Manpower

Revenue Per Employee253.8K
Revenue Per Executive533K
Net Loss Per Employee666K
Net Loss Per Executive1.4M
Working Capital Per Employee542K
Working Capital Per Executive1.1M

Complementary Tools for Arcadia Stock analysis

When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Money Managers
Screen money managers from public funds and ETFs managed around the world